Aromatase and its inhibitors in breast cancer treatment--overview and perspective.

Abstract

Estrogen has an important role in stimulating the growth of breast carcinomas. Inhibition of estrogen production is therefore a logical treatment strategy. A number of selective inhibitors have been developed against aromatase, a cytochrome P-450 enzyme which catalyzes the rate limiting step in the biosynthesis of estrogens. The mechanisms of the aromatase reaction, current knowledge of the enzyme, and regulation of its expression are discussed as the basis for inhibitor development. Two classes of aromatase inhibitors, steroidal and non-steroidal compounds, are now coming into use. Among the steroid substrate analogues, 4-hydroxyandrostenedione (4-OHA) has been shown to be effective in breast cancer patients with advanced disease and was recently approved for treatment in the United Kingdom. Several different classes of compounds which act as aromatase inhibitors are currently in clinical trials and should provide breast cancer patients with a number of treatment options. Among these are highly potent and selective non-steroidal inhibitors which have recently been found to suppress plasma and urinary estrogens over 95% in breast cancer patients. The potency of these newer aromatase inhibitors provides the opportunity to determine whether complete suppression of estrogen production and action will result in enhanced tumor regression.

• Authors: A M Brodie, R J Santen
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 30 Issue 1 Pg. 1-6 ( 1994) ISSN: 0167-6806 [Print] Netherlands
• PMID: 7949200 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Aromatase Inhibitors
• Steroids
• Androstenedione
• formestane

Topics

• Androstenedione (analogs & derivatives, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Aromatase Inhibitors
• Breast Neoplasms (drug therapy)
• Female
• Humans
• Steroids (therapeutic use)